Literature DB >> 24136715

Complex sleep apnea.

Harish Rao1, Robert Joseph Thomas.   

Abstract

OPINION STATEMENT: Complex sleep apnea currently refers to the emergence and persistence of central apneas and hypopneas following the application of positive airway pressure therapy in patients with obstructive sleep apnea. However, this narrow definition is an "outcome" and does not capture the spectrum of pathological activation of the respiratory chemoreflex in sleep apnea. The International Classification of Sleep Disorders - 3rd edition recognizes the phenomenon of Treatment-Related Central Sleep Apnea, but the phenotype is usually evident prior to onset of therapy. The key polysomnographic characteristics of chemoreflex modulated and mediated sleep apnea are nonrapid eye movement (NREM) dominance of respiratory events, short (<30 seconds) or long (>60 seconds) cycle time with a self-similar metronomic timing, and spontaneous improvement during rapid eye movement (REM) sleep. Thus, the majority of chemoreflex effects go unrecognized due to the bias toward obstructive sleep apnea's current scoring criteria. Any treatment of apparently obstructive sleep apnea, including surgery and oral appliances, can expose chemoreflex-driven instabilities. As both sleep fragmentation and a narrow CO2 reserve or increased loop gain drive the disease, sedatives (to induce longer periods of stable NREM sleep and reduce the destabilizing effects of arousals in NREM sleep) and CO2-based stabilization approaches are logical. Adaptive ventilation reduces mean hyperventilation yet can induce ventilator-patient desynchrony, while enhanced expiratory rebreathing space (EERS, dead space during positive pressure therapy) and CO2 manipulation directly stabilize respiratory control by moving CO2 above the apnea threshold. Carbonic anhydrase inhibition can provide further adjunctive benefits. Novel pharmacological approaches may target mediators of carotid body hypoxic sensitization, such as the balance between gas neurotransmitters. In complex apnea patients, single mode therapy is unlikely to be successful, and the power of multi-modality therapy should be harnessed for optimal outcomes.

Entities:  

Year:  2013        PMID: 24136715     DOI: 10.1007/s11940-013-0260-7

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  29 in total

Review 1.  Carbon monoxide (CO) and hydrogen sulfide (H(2)S) in hypoxic sensing by the carotid body.

Authors:  Nanduri R Prabhakar
Journal:  Respir Physiol Neurobiol       Date:  2012-06-02       Impact factor: 1.931

2.  The development of central sleep apnea with an oral appliance.

Authors:  Alon Y Avidan
Journal:  Sleep Med       Date:  2005-09-27       Impact factor: 3.492

3.  A case study involving the combination treatment of an oral appliance and auto-titrating CPAP unit.

Authors:  Martin A Denbar
Journal:  Sleep Breath       Date:  2002-09       Impact factor: 2.816

Review 4.  Role of nocturnal rostral fluid shift in the pathogenesis of obstructive and central sleep apnoea.

Authors:  Laura H White; T Douglas Bradley
Journal:  J Physiol       Date:  2012-12-10       Impact factor: 5.182

5.  Predictors of response to a nasal expiratory resistor device and its potential mechanisms of action for treatment of obstructive sleep apnea.

Authors:  Amit V Patel; Dennis Hwang; Maria J Masdeu; Guo-Ming Chen; David M Rapoport; Indu Ayappa
Journal:  J Clin Sleep Med       Date:  2011-02-15       Impact factor: 4.062

6.  Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies.

Authors:  Giuseppina De Simone; Anna Di Fiore; Valeria Menchise; Carlo Pedone; Jochen Antel; Angela Casini; Andrea Scozzafava; Michael Wurl; Claudiu T Supuran
Journal:  Bioorg Med Chem Lett       Date:  2005-05-02       Impact factor: 2.823

7.  Patients with obstructive sleep apnea syndrome benefit from acetazolamide during an altitude sojourn: a randomized, placebo-controlled, double-blind trial.

Authors:  Yvonne Nussbaumer-Ochsner; Tsogyal D Latshang; Silvia Ulrich; Malcolm Kohler; Robert Thurnheer; Konrad E Bloch
Journal:  Chest       Date:  2011-06-09       Impact factor: 9.410

8.  Effect of acetazolamide and autoCPAP therapy on breathing disturbances among patients with obstructive sleep apnea syndrome who travel to altitude: a randomized controlled trial.

Authors:  Tsogyal D Latshang; Yvonne Nussbaumer-Ochsner; Rahel M Henn; Silvia Ulrich; Christian M Lo Cascio; Bruno Ledergerber; Malcolm Kohler; Konrad E Bloch
Journal:  JAMA       Date:  2012-12-12       Impact factor: 56.272

9.  Differing relationship of nocturnal fluid shifts to sleep apnea in men and women with heart failure.

Authors:  Takatoshi Kasai; Shveta S Motwani; Dai Yumino; Susanna Mak; Gary E Newton; T Douglas Bradley
Journal:  Circ Heart Fail       Date:  2012-06-07       Impact factor: 8.790

10.  Inhibition of hydrogen sulfide restores normal breathing stability and improves autonomic control during experimental heart failure.

Authors:  Rodrigo Del Rio; Noah J Marcus; Harold D Schultz
Journal:  J Appl Physiol (1985)       Date:  2013-02-28
View more
  1 in total

1.  Prevalence and Characteristics of Central Compared to Obstructive Sleep Apnea: Analyses from the Sleep Heart Health Study Cohort.

Authors:  Lucas M Donovan; Vishesh K Kapur
Journal:  Sleep       Date:  2016-07-01       Impact factor: 5.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.